<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400332</url>
  </required_header>
  <id_info>
    <org_study_id>CA027-002</org_study_id>
    <secondary_id>2018-000340-26</secondary_id>
    <nct_id>NCT03400332</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers</brief_title>
  <official_title>A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate experimental medication BMS-986253 in combination&#xD;
      with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">June 8, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AE)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2, participants with advanced melanoma, selected by baseline serum interleukin-8 (IL-8) level using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (mDOR) per response evaluation criteria in solid tumors (RECIST) v1.1</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) to BMS-986253</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biomarker concentration</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum concentration at the end of a dosing interval (CTAU)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration at the end of the dosing interval (CTROUGH)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 1 and Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2, participants with advanced melanoma, using RECIST v1.1 (regardless of baseline serum IL-8 levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1A: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1C: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2A: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2B: Placebo + nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986253</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_label>Part 1B: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_label>Part 1C: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_label>Part 2A: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_label>Part 1B: BMS-986253 + nivolumab</arm_group_label>
    <arm_group_label>Part 1C: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_label>Part 2A: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_label>Part 2B: Placebo + nivolumab + ipilimumab</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1C: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_label>Part 2A: BMS-986253 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_label>Part 2B: Placebo + nivolumab + ipilimumab</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>YERVOY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2B: Placebo + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,&#xD;
             recurrent and/or unresectable) with measurable disease per RECIST v1.1&#xD;
&#xD;
          -  At least 1 lesion accessible for biopsy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with CNS metastases as the only site of active disease (Participants with&#xD;
             controlled brain metastases; however, will be allowed to enroll)&#xD;
&#xD;
          -  Participants with active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Participants with conditions requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10mg prednisone equivalents) or other immunosuppressive medications within 14 days&#xD;
             of study treatment administration&#xD;
&#xD;
          -  Participants with a known history of testing positive for Human Immunodeficiency Virus&#xD;
             (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)&#xD;
&#xD;
          -  Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior&#xD;
             anti-cancer therapy and initiation of study therapy&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0059</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology P.A.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Sharfman, Site 0003</last_name>
      <phone>410-502-5140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, Site 0005</last_name>
      <phone>551-996-4725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Icahn School Of Medicine At Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Marron, Site 0025</last_name>
      <phone>212-824-7259</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Dallos, Site 0002</last_name>
      <phone>212-342-3970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Ulahannan, Site 0028</last_name>
      <phone>405-271-8778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute And Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diwakar Davar, Site 0001</last_name>
      <phone>412-623-5396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Simmons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104-3927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0058</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0037</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0029</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0055</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0056</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0034</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0053</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0052</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0054</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Forlì</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0042</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Ascierto, Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rozzano-milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Alonso Gordoa, Site 0045</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno, Site 0022</last_name>
      <phone>+34915504800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Calvo Aller, Site 0023</last_name>
      <phone>+34917567825</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen De La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Manuel Trigo Perez, Site 0044</last_name>
      <phone>+34951032467</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Melero, Site 0021</last_name>
      <phone>+34948255400ext2733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Univ. de Santiago-CHUS</name>
      <address>
        <city>Santiago Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Rodriguez, Site 0047</last_name>
      <phone>+34981950511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Vaudois Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Orcurto, Site 0040</last_name>
      <phone>+41795567517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Joerger, Site 0041</last_name>
      <phone>+41714941111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zuerich</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Britschgi, Site 0039</last_name>
      <phone>+41442552214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

